CBS News: How AI Is Accelerating Safer, More Personalized Drug Discovery
In a CBS News interview, Dotmatics VP Phil Mounteney explains how their internally built AI models accelerate drug discovery by analyzing early-phase scientific data to reduce development timelines and costs while enhancing safety and personalization in therapies.
CBS News: How AI Is Accelerating Safer, More Personalized Drug Discovery
WRGB 5-12-25 Dotmatics
Press O for more options

Click for sound
1:10
In a recent CBS News New York interview, Dotmatics VP of Science and Technology, Phil Mounteney, shares how artificial intelligence is reshaping the drug discovery process—helping researchers accelerate timelines, reduce costs, and deliver safer, more effective therapies to market.
By using AI to analyze scientific data generated in early-phase research, Dotmatics enables teams to cut years off traditional development cycles for vaccines and personalized medicine. These AI models are built and stored internally—ensuring data privacy while driving innovation at scale.
Watch the full interview to learn how Dotmatics is helping the healthcare industry move faster and smarter toward breakthrough cures.
Learn More About Dotmatics
Schedule a meeting with our team to learn more about Luma's AI capabilities.